The prophylactic and therapeutic effects of BCG on the tumors induced by 3-methylcholanthrene (MCA) were studied comparatively between two inbred mouse strains, SWM/Ms and C3H/He, the first tumor appeared 5 weeks after MCA and the cumulative tumor incidence reached almost 100% within 20 weeks. On the other hand, the first tumor appeared 8 weeks after MCA in SWM/Ms, the number of tumor-bearers increased more slowly than in C3H / He, and the final tumor incidence (at 30 weeks) was about 90-80%. Single subcutaneous injection with BCG 2 weeks prior to MCA significantly protected SWM/Ms from tumor development, but not in C3H/He. These tumors, once appeared grew progressively and killed the hosts equally in both the strains. Intratumor (i.t.) injection with BCG showed more or less therapeutic effects in SWM/Ms; most tumors regressed or retarded after BCG. The time period after tumor-appearance to tumor-death was prolonged in most of SWM/Ms mice given it. injection with BCG, except a few mice that died earlier than non-treated controls after BCG. Contrary, no therapeutic effect of it. injection with BCG was observed in C3H/He. Different host responses to BCG between SWM/Ms and C3H/He were found by the peritoneal macrophage disappearance test and the footpad reaction test; SWM/Ms was a highresponder to BCG and C3H/He was a low-responder.
INTRODUCTION
A huge number of reports have been published on the immunotherapeutic and immunoprophylactic effects of BCG against human cancers (Bast et al., 1974; Mastrangelo, Berd and Bellet, 1976) . Although early studies (Davignon et al., 1970; Rosenthal et al., 1972) indicated that mortality from leukemia could be reduced by BCG vaccination, most studies failed to confirm these observations. General conclusion is difficult to be reached regarding the prophylactic efficacy of BCG against human cancer. The most convincing therapeutic effects of BCG seem to be demonstrated in melanoma given intratumor (i.t.) injection with BCG (Morton et al., 1970; Pinsky et al., 1973 Pinsky et al., , 1976 Guttetman et al., 1976) . However, efficacy of i.t. injection with BCG on miscellaneous tumors is too incomplete to allow any valid conclusion (Mastrangelo et al., 1976) . To evaluate properly the prophylactic and therapeutic efficacy of BCG, information from animal experiments using autochthonous tumor systems must be important at this stage of study.
Previously we reported such effects of BCG on 3-methylcholanthrene (MCA)-induced autochthonous tumors in SWM/Ms mice (Tokunaga et al., 1974) . During the observation period of 35 weeks after single subcutaneous injections with MCA, more than 800 of control mice developed tumors. Intradermal (i.d.) injection with BCG 2 weeks before MCA administration significantly decreased tumor incidence. BCG injected directly into the tumors within 3 days of tumor detection showed therapeutic effects on about 50% of the tumors, while control tumors without BCG treatment grew progressively and killed the hosts. A similar experiment was repeated using C3H/He mice instead of SWM/Ms mice in expectation of obtaining results similar to the previous ones. However, neither prophylactic nor therapeutic effect was observed. Therefore, similar experiments were repeated using both SWM/Ms and C3H/He mice simultaneously. The present paper describes the results of these experiments and explains the different antitumor effects of BCG on these two mouse strains in terms of different host response to BCG.
MATERIALS AND METHODS
Mice: Inbred SWM/Ms mice were obtained from the National Institute of Genetics, Mishima, Shizuoka, Japan in 1971, and have been bred in this laboratory. Inbred C3H/He mice were purchased from Funabashi Animal Farm, Chiba, Japan. All the mice were female and about 8 weeks of age at the beginning of experiments. They were fed with commercial pellets and tap water ad libitum.
MCA administration: Mice were given subcutaneous (s.c.) injections on the right rump with 0.5-mg MCA dissolved in 0.1-ml olive-oil.
Tumor incidence: In the previous work, we noticed that tumors with diameters of over 5 mm grew progressively, resulting in consistent death of the hosts (Kataoka et al., 1972; Tokunaga et al., 1974) . Therefore, tumor incidence was expressed as the ratio of the number of mice bearing tumors bigger than 5 mm in diameter to the total number of mice. Some mice died without visible tumors during the observation period. The probability that an animal would remain tumor free was estimated every week, with deaths of tumor-free animals counted by the statistical analysis of the life-table method (Pike, 1966; Tokunaga et al., 1974) .
BCG: Lyophilized BCG manufactured by the Japan BCG Laboratory, Tokyo, Japan, was suspended in physiologic saline, washed once and adjusted to an appropriate concentration of viable units. during the observation period; in group A, two died in 9 weeks after MCA; in group B one each in 6, 8 and 13 weeks; in group C, one in 14 weeks; in group D, one each in 6, 9 and 10 weeks after MCA treatment. The probability that an animal would remain tumor free was estimated every week by the statistical analysis of the life-table method, and the cumulative tumor incidence (%) calculated statistically for each group are plotted in Fig. 1 . The first tumors appeared 5 weeks after MCA injection, and the number of tumor-bearing animals increased rapidly from 8 to 11 weeks. In 13 weeks, almost all animals produced tumors despite of BCG administration. The calculated tumor incidence at the end of the experiment was 98.0% in group A, 95.6% in group B, 98.0% in group C and 97.1% in group D. There existed no significant difference in the tumor incidence among the four groups throughout the observation period. A similar experiment performed previously using SWM/Ms mice (Tokunaga et al., 1974) weeks after MCA administration. The estimated percentages of cumulative tumor incidence for each group were calculated with adjustment for non-tumor deaths (Fig. 2) .
In C3H-control, the first tumors appeared 5 weeks after MCA injection; the number of tumor-bearing mice increased rapidly. Within 20 weeks, 100% of animals beared tumors. In SWM-control group, on the other hand, the first tumors appeared 8 weeks after MCA and the number of tumor-bearers increased relatively slowly till the 23rd week after MCA. The tumor incidence at the end of the experiment was 92.2%. All of C3H-control group died within 21 weeks after MCA, except one that died in 25 weeks. On the other hand, eight mice of SWM-control group survived for more than 21 weeks; one of the eight mice died in 24 weeks after MCA, four died in 25 weeks, one died in 28 weeks and two survived for more than 30 weeks. Differences in the cumulative incidence 10, 11 and 20 weeks after MCA between C3H-control and SWM-control groups were significant by both the Fisher's exact test and the x2 test at a probability of 0.05, and those in 8 and 13 weeks were significant at a probability of 0.01.
In C3H-BCG group, the first tumor appeared also in 5 weeks, and all mice died within 21 weeks; exceptionally two died in 22 weeks. Difference in the tumor incidence between C3H-control and C3H-BCG was insignificant throughout the experimental period (P=0.05). In SWM-BCG group, on the contrary, the first tumor appeared 7 weeks after MCA, and the number of tumorbearers increased more slowly than SWM-control. Differences in the tumor incidence between SWM-control and SWM-BCG were significant in 9, 10 and 11 weeks after MCA (P=0.05) and in 12, 14 and 18 weeks (P=0.10). Thus, prophylactic effect of BCG against MCA-induced tumors was clear in SWM / Ms but not in C3H/He.
Effects of BCG Injection into MCA-induced Tumors
In the course of Exp. I described above, BCG was injected directly into all of the tumors grown to 5 mm or more in diameter except for group D. In group D, three out of four tumors were given i.t. injection with BCG as they developed and the rest were left untreated as control; 34 of 44 tumors were given BCG and 10 were the controls. The results are summarized in Table I . As references, our previous data obtained in similar experiments with SWM/Ms (Tokunaga et al., 1974) are included in the table. No tumor regression occurred after i.t. injection with BCG in any of the groups of C3H/He or the control group of SWM/Ms, while four of 12 tumors (33.3%) regressed, at least once, in SWM/Ms presensitized with BCG (group A in Table I ) and five of 30 (16.7%) in SWM/Ms without presensitization (a part of group D). More than 80% of tumors in C3H/He grew progressively and killed the hosts within 10 weeks after tumor appearance, regardless of presensitization or i.t. injection with BCG.
In the course of Exp. II described above, BCG was injected also directly EFFECTS OF BCG ON A UTOCHTHONO US TUMORS All tumorbearing mice received it. injection with BCG within 3 days when a tumor grew to more than 5 mm in diameter, except in the mice marked with*** in group D, which were given no i.t. injection with BCG. ** Mice died within 2 weeks after i .t. injection with BCG. *** See above (*). **** These data were reported previously (Tokunaga et al ., 1974) . 
Host Responses to BCG
In order to know possible differences in host immune response to BCG between SWM Ms and C3H / Ms, the peritoneal macrophage disappearance test and the footpad reaction test were performed using those mice sensitized with BCG 2 weeks earlier. The results are shown in Table III. In the peritoneal macrophage disappearance test, the loss of the macrophages with PPD injection was remarkable in SWM / Ms, while it was weak in C3H/He. In the footpad reaction test with PPD, it was also shown that SWM/Ms was a high responder strain to BCG, while C3H/He was a low responder.
DISCUSSION
A large number of reports on the antitumor effects of BCG against experimental tumors have been published (Bast et al., 1974 (Bast et al., , 1976 . They suggested that a variety of factors influence largely the immunoprophylactic and immunotherapeutic effects of BCG. For instance, the administration timing of BCG in response to oncogenic agents is an important factor for successful prophylactic effects of BCG against tumors (Old et al., 1961; Lemonde et al., 1966; Sjogren and Ankerst, 1969; Lavrin et al., 1973; Tokunaga et al., 1974 (Bast et al., 1974 (Bast et al., , 1976 Zbar et al., 1976 in the National Institute of Genetics , Mishima, Japan. Although the histocompatibility of SWM/Ms is unknown, it is obvious that this strain is histoincompatible to C3H/He (H-2b) , because antiserum prepared in C3H/He against SWM/Ms spleen cells was cytotoxic to the SWM/Ms lymphocytes , and vice versa, and a transplantable fibrosarcoma, K5 (Tokunaga et al ., 1972) , that is syngeneic to SWM/Ms, was never taken by C3H/He (Nakamura , R. M. and Tokunaga, T., unpublished data). As described in the present paper , these two strains were shown to respond differently to BCG . Genetic analysis of the immune response to BCG in F1, F2 and backcross of these two strains showed that the high responsiveness to BCG observed in SWM/Ms was a feature of dominant over low responsiveness in C3H/He, and transmitted according to the Mendel's Laws (Nakamura and Tokunaga, 1978) . Obviously , tumor incidence with MCA was also higher in C3H / He than SWM / Ms, as indicated in this paper . Whether or not the high incidence of tumor in C3H/He links with the low responsiveness to BCG or the hlstocompatibility or both is unknown and under study . The spleen cells from SWM/Ms mice receiving single subcutaneous injections with BCG 2 weeks before responded well to PPD in vitro, while those from C3H/He treated by the same way did not (Nakamura et al ., 1978) . This means that production of BCG-sensitized T lymphocytes after BCG may be inhibited in C3H/He. Our previous data (Tokunaga and Yamamoto , 1977) obtained with athymic nude mice and their syngeneic tumor , KKN-1, indicated that growing solid tumors did not regress after i .t. injection with BCG in nu/nu mice, while did so in nu/+ in the same genetic background , suggesting that the 1st mechanism described above alone can not inhibit the growth of once established, growing tumors; the 2nd or the 3rd or both the mechanisms connected with T cell functions must be required . These may explain the fact that auotchthonous tumors in C3H/He were not regressed by i .t. injection with BCG, in terms of lack of the 2nd mechanism , and therefore the 3rd, too, in these mice after BCG.
